Effects of multifunctional antioxidants on mitochondrial dysfunction and amyloid-β metal dyshomeostasis

Hiroyoshi Kawada, Karen Blessing, Tomomi Kiyota, Theodor Woolman, Lee Winchester, Peter F Kador

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background: Redox-active metal dyshomeostasis and oxidative stress are associated with mitochondrial dysfunction and amyloid-β (Aβ) neurotoxicity that are linked to both the development of age-related macular degeneration (AMD) and Alzheimer's disease (AD). As potential therapeutic agents, orally active multifunctional antioxidants (MFAOs) possessing two independent functional groups capable of binding redox-active metals and scavenging free radicals have been synthesized. Objective: To determine whether MFAOs affect mitochondrial function and reduce the presence of Aβ plaque formation. Methods: The MFAOs were evaluated in cultured SH-SY5Y cells and ARPE-19 cells. MFAO effects on mitochondrial function were investigated using rhodamine 123 staining after 2 hour exposure to MnCl2. MFAO effects on Aβ:Zn complex formation were evaluated with Zinquin staining and the ability of the Aβ:Zn complex to be degraded by matrix metalloproteinase-2 (MMP-2). The ability of MFAOs to reduce Aβ plaque in the brain was determined by orally feeding MFAO for one year to B6;129-Psen1tm1Mpm Tg(AßPPSwe, tauP301L) 1Lfa/Mmjax transgenic mice. Aβ levels were determined by ELISA. Results: MFAOs neither adversely affected mitochondrial signaling nor labile cytoplasmic zinc levels. MFAOs protected cells against Mn2+-induced mitochondrial dysfunction. MFAOs also removed zinc from the Aβ:Zn complex so that Aβ plaque could be degraded by MMP-2. Zinquin staining indicated that the removed zinc was present in the cytoplasm as labile zinc. Orally administered MFAOs reduced the brain levels of both Aβ40 and Aβ42 isoforms of Aβ. Conclusion: These studies demonstrate that these MFAOs have metal attenuating properties with therapeutic potential in the treatment of both AMD and AD.

Original languageEnglish (US)
Pages (from-to)297-307
Number of pages11
JournalJournal of Alzheimer's Disease
Volume44
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Amyloid
Antioxidants
Metals
Zinc
Aptitude
Matrix Metalloproteinase 2
Macular Degeneration
Staining and Labeling
Oxidation-Reduction
Alzheimer Disease
Rhodamine 123
Brain
Transgenic Mice
Free Radicals
Protein Isoforms
Cytoplasm
Oxidative Stress
Therapeutics
Enzyme-Linked Immunosorbent Assay

Keywords

  • Age-related macular degeneration
  • Alzheimer's disease
  • Amyloid-β
  • Clioquinol
  • JAX transgenic Alzheimer mouse
  • Mitochondrial dysfunction
  • Multifunctional antioxidants

ASJC Scopus subject areas

  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Effects of multifunctional antioxidants on mitochondrial dysfunction and amyloid-β metal dyshomeostasis. / Kawada, Hiroyoshi; Blessing, Karen; Kiyota, Tomomi; Woolman, Theodor; Winchester, Lee; Kador, Peter F.

In: Journal of Alzheimer's Disease, Vol. 44, No. 1, 01.01.2015, p. 297-307.

Research output: Contribution to journalArticle

Kawada, Hiroyoshi ; Blessing, Karen ; Kiyota, Tomomi ; Woolman, Theodor ; Winchester, Lee ; Kador, Peter F. / Effects of multifunctional antioxidants on mitochondrial dysfunction and amyloid-β metal dyshomeostasis. In: Journal of Alzheimer's Disease. 2015 ; Vol. 44, No. 1. pp. 297-307.
@article{f7399028a5d64bfba9bb29fb85cd6da2,
title = "Effects of multifunctional antioxidants on mitochondrial dysfunction and amyloid-β metal dyshomeostasis",
abstract = "Background: Redox-active metal dyshomeostasis and oxidative stress are associated with mitochondrial dysfunction and amyloid-β (Aβ) neurotoxicity that are linked to both the development of age-related macular degeneration (AMD) and Alzheimer's disease (AD). As potential therapeutic agents, orally active multifunctional antioxidants (MFAOs) possessing two independent functional groups capable of binding redox-active metals and scavenging free radicals have been synthesized. Objective: To determine whether MFAOs affect mitochondrial function and reduce the presence of Aβ plaque formation. Methods: The MFAOs were evaluated in cultured SH-SY5Y cells and ARPE-19 cells. MFAO effects on mitochondrial function were investigated using rhodamine 123 staining after 2 hour exposure to MnCl2. MFAO effects on Aβ:Zn complex formation were evaluated with Zinquin staining and the ability of the Aβ:Zn complex to be degraded by matrix metalloproteinase-2 (MMP-2). The ability of MFAOs to reduce Aβ plaque in the brain was determined by orally feeding MFAO for one year to B6;129-Psen1tm1Mpm Tg(A{\ss}PPSwe, tauP301L) 1Lfa/Mmjax transgenic mice. Aβ levels were determined by ELISA. Results: MFAOs neither adversely affected mitochondrial signaling nor labile cytoplasmic zinc levels. MFAOs protected cells against Mn2+-induced mitochondrial dysfunction. MFAOs also removed zinc from the Aβ:Zn complex so that Aβ plaque could be degraded by MMP-2. Zinquin staining indicated that the removed zinc was present in the cytoplasm as labile zinc. Orally administered MFAOs reduced the brain levels of both Aβ40 and Aβ42 isoforms of Aβ. Conclusion: These studies demonstrate that these MFAOs have metal attenuating properties with therapeutic potential in the treatment of both AMD and AD.",
keywords = "Age-related macular degeneration, Alzheimer's disease, Amyloid-β, Clioquinol, JAX transgenic Alzheimer mouse, Mitochondrial dysfunction, Multifunctional antioxidants",
author = "Hiroyoshi Kawada and Karen Blessing and Tomomi Kiyota and Theodor Woolman and Lee Winchester and Kador, {Peter F}",
year = "2015",
month = "1",
day = "1",
doi = "10.3233/JAD-132471",
language = "English (US)",
volume = "44",
pages = "297--307",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "1",

}

TY - JOUR

T1 - Effects of multifunctional antioxidants on mitochondrial dysfunction and amyloid-β metal dyshomeostasis

AU - Kawada, Hiroyoshi

AU - Blessing, Karen

AU - Kiyota, Tomomi

AU - Woolman, Theodor

AU - Winchester, Lee

AU - Kador, Peter F

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Background: Redox-active metal dyshomeostasis and oxidative stress are associated with mitochondrial dysfunction and amyloid-β (Aβ) neurotoxicity that are linked to both the development of age-related macular degeneration (AMD) and Alzheimer's disease (AD). As potential therapeutic agents, orally active multifunctional antioxidants (MFAOs) possessing two independent functional groups capable of binding redox-active metals and scavenging free radicals have been synthesized. Objective: To determine whether MFAOs affect mitochondrial function and reduce the presence of Aβ plaque formation. Methods: The MFAOs were evaluated in cultured SH-SY5Y cells and ARPE-19 cells. MFAO effects on mitochondrial function were investigated using rhodamine 123 staining after 2 hour exposure to MnCl2. MFAO effects on Aβ:Zn complex formation were evaluated with Zinquin staining and the ability of the Aβ:Zn complex to be degraded by matrix metalloproteinase-2 (MMP-2). The ability of MFAOs to reduce Aβ plaque in the brain was determined by orally feeding MFAO for one year to B6;129-Psen1tm1Mpm Tg(AßPPSwe, tauP301L) 1Lfa/Mmjax transgenic mice. Aβ levels were determined by ELISA. Results: MFAOs neither adversely affected mitochondrial signaling nor labile cytoplasmic zinc levels. MFAOs protected cells against Mn2+-induced mitochondrial dysfunction. MFAOs also removed zinc from the Aβ:Zn complex so that Aβ plaque could be degraded by MMP-2. Zinquin staining indicated that the removed zinc was present in the cytoplasm as labile zinc. Orally administered MFAOs reduced the brain levels of both Aβ40 and Aβ42 isoforms of Aβ. Conclusion: These studies demonstrate that these MFAOs have metal attenuating properties with therapeutic potential in the treatment of both AMD and AD.

AB - Background: Redox-active metal dyshomeostasis and oxidative stress are associated with mitochondrial dysfunction and amyloid-β (Aβ) neurotoxicity that are linked to both the development of age-related macular degeneration (AMD) and Alzheimer's disease (AD). As potential therapeutic agents, orally active multifunctional antioxidants (MFAOs) possessing two independent functional groups capable of binding redox-active metals and scavenging free radicals have been synthesized. Objective: To determine whether MFAOs affect mitochondrial function and reduce the presence of Aβ plaque formation. Methods: The MFAOs were evaluated in cultured SH-SY5Y cells and ARPE-19 cells. MFAO effects on mitochondrial function were investigated using rhodamine 123 staining after 2 hour exposure to MnCl2. MFAO effects on Aβ:Zn complex formation were evaluated with Zinquin staining and the ability of the Aβ:Zn complex to be degraded by matrix metalloproteinase-2 (MMP-2). The ability of MFAOs to reduce Aβ plaque in the brain was determined by orally feeding MFAO for one year to B6;129-Psen1tm1Mpm Tg(AßPPSwe, tauP301L) 1Lfa/Mmjax transgenic mice. Aβ levels were determined by ELISA. Results: MFAOs neither adversely affected mitochondrial signaling nor labile cytoplasmic zinc levels. MFAOs protected cells against Mn2+-induced mitochondrial dysfunction. MFAOs also removed zinc from the Aβ:Zn complex so that Aβ plaque could be degraded by MMP-2. Zinquin staining indicated that the removed zinc was present in the cytoplasm as labile zinc. Orally administered MFAOs reduced the brain levels of both Aβ40 and Aβ42 isoforms of Aβ. Conclusion: These studies demonstrate that these MFAOs have metal attenuating properties with therapeutic potential in the treatment of both AMD and AD.

KW - Age-related macular degeneration

KW - Alzheimer's disease

KW - Amyloid-β

KW - Clioquinol

KW - JAX transgenic Alzheimer mouse

KW - Mitochondrial dysfunction

KW - Multifunctional antioxidants

UR - http://www.scopus.com/inward/record.url?scp=84920771154&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920771154&partnerID=8YFLogxK

U2 - 10.3233/JAD-132471

DO - 10.3233/JAD-132471

M3 - Article

C2 - 25227315

AN - SCOPUS:84920771154

VL - 44

SP - 297

EP - 307

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 1

ER -